N2off, INC 10-Q quarterly reports

Nexentis Technologies Inc. reported a net loss of $6.59 million for Q1 2026, impacted by a $6.3 million goodwill impairment charge related to its MitoCareX subsidiary, alongside strategic divestitures and ongoing development in biotechnology and renewable energy.

N2OFF, Inc. reports Q3 2025 results, highlighting strategic shifts into oncology and renewable energy, a significant MitoCareX acquisition, and ongoing capital raises amidst a going concern warning.

N2OFF, Inc. reported a significantly wider net loss in Q2 2025, driven by increased operating expenses and fair value adjustments, despite a slight revenue increase and strategic expansion into renewable energy.

N2OFF Inc. reports increased revenue for Q1 2025 driven by US client sales, alongside strategic investments in renewable energy projects and a focus on improving financial stability.

N2OFF Inc. reports a net loss for the third quarter of 2024, impacted by decreased revenues and increased operating expenses, while navigating ongoing geopolitical and financial challenges.

N2OFF Inc. reports a decrease in revenue and a net loss for the second quarter of 2024, while navigating operational challenges in Israel.

N2OFF Inc. reports a decrease in revenue and a net loss for the first quarter of 2024, while navigating strategic changes and ongoing market challenges.